Authorization

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

SAN DIEGO, Dec. 1, 2021 /PRNewswire/ --A Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma.
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
"We believe orphan-drug designation underscores the recognition of INBRX-109 as a promising therapeutic for patientsA with metastatic or unresectable chondrosarcoma, a patient community currently with no other viable options," said Inhibrx Chief Executive Officer Mark Lappe. The FDA's Office of Orphan Products Development grants orphan designation status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan-drug designation provides certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity in the U.S. upon regulatory approval.About Chondrosarcoma
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
24252627282930
31